The titer of antibody against core antigen of hepatitis B virus in the immunoglobulin M class (IgM anti-HBc) was determined by an IgM capture assay of reduced sensitivity (30 arbitrary units). Such infections may be detected by antibody (anti-HBc) against HBV core antigen (HBcAg) (13, 19) . Anti-HBc persists for a long time after acute or transient inapparent infections, and it is permanently present in chronic infections. Acute infections may be differentiated from past infections by assay of specific immunoglobulin M (IgM) antibodies, and many studies have shown the presence of IgM anti-HBc in acute hepatitis B (1, 5, 7, 14, 15, 22-24, 28, 33). Its diagnostic value has, however, been drawn into doubt (16) because IgM anti-HBc has also been detected in many chronic carriers of HBsAg (10, 15, 20, 31) . Moreover, the very high sensitivity of the widely used IgM capture assay makes IgM anti-HBc sometimes detectable for years after the acute infection (1, 15, 28) , if the sensitivity is not purposely reduced.
Acute viral hepatitis may be caused by hepatitis A virus, hepatitis B virus (HBV), hepatitis delta virus, and an unknown number of not yet identified non-A, non-B hepatitis viruses. In many regions HBV is the most important cause of acute and chronic viral hepatitis. Diagnosis of HBV infections is usually achieved by assay of surplus HBV surface antigen (HBsAg) in the blood, but this marker does not distinguish between acute, chronic symptomatic, and chronic asymptomatic HBV infections. Moreover, HBsAg may be undetectable in a certain proportion of acute or even chronic infections.
Such infections may be detected by antibody (anti-HBc) against HBV core antigen (HBcAg) (13, 19) . Anti-HBc persists for a long time after acute or transient inapparent infections, and it is permanently present in chronic infections. Acute infections may be differentiated from past infections by assay of specific immunoglobulin M (IgM) antibodies, and many studies have shown the presence of IgM anti-HBc in acute hepatitis B (1, 5, 7, 14, 15, 22-24, 28, 33) . Its diagnostic value has, however, been drawn into doubt (16) because IgM anti-HBc has also been detected in many chronic carriers of HBsAg (10, 15, 20, 31) . Moreover, the very high sensitivity of the widely used IgM capture assay makes IgM anti-HBc sometimes detectable for years after the acute infection (1, 15, 28) , if the sensitivity is not purposely reduced.
In view of this situation, it has been noted that only quantitation of IgM anti-HBc could allow distinction of recent, chronic, and past HBV infections (15, 28, 32) . There is, however, no general agreement in the literature and among the producers of test kits on whether a clear distinction is possible at all and which titer could serve as the cutoff level. This uncertainty originates partly from the lack of a generally accepted reference sample.
This study describes how the assay can be standardized, and it reports quantitative data on several hundred cases of acute, chronic, and past HBV infections. The data show that 
MATERIALS AND METHODS
Reagents for the assay of IgM anti-HBc. Aggregated IgG was prepared from a pool of anti-HBc-negative, recalcified human plasmas (NHP) by gel chromatography through BioGel A5M (Bio-Rad Laboratories, Richmond, Calif.) and by subsequent heating of the IgG main fraction to 65°C for 10 min.
Microplates (Nunc Il; Nunc, Roskilde, Denmark) were incubated with a 1:4,000 dilution of anti-,u-chain antiserum (Dakopatts, Hamburg, Federal Republic of Germany) in 0.075 M carbonate buffer (pH 9.6) overnight at 4°C. The solution was aspirated, and 0.1% bovine serum albumin in 0.1 M NaCl-10 mM Tris hydrochloride (pH 7.4)-i mM EDTA (buffer for all dilutions) was added for 2 h at room temperature. Plates were emptied, washed three times with 0.01 M sodium phosphate (pH 7.4)-0.13 M NaCl-0.5% Tween 20 (buffer for all washings), air dried, sealed in plastic bags, and stored at 4°C until use.
HBcAg was isolated from HBV-infected human liver and partially purified by zonal sedimentation as described previously (14) . Recently, HBcAg from a transfected Eschericlhia coli strain (V. Bruss and W. H. Gerlich, unpublished data) was also used. This antigen was purified from bacterial lysate by zonal sedimentation as described before and further purified by gel chromatography through Bio-Gel A15M. Before use, HBcAg was diluted in 1% NHP.
The anti-HBc IgG fraction was isolated from HBsAgpositive plasma which had a high titer of anti-HBc (1:160,000), but no anti-hepatitis B surface antibody, antihepatitis B e antibody, or hepatitis B e antigen, using threefold precipitation with 17% (wt/wt) sodium sulfate. This IgG was coupled with peroxidase as described previously As was shown previously, the results ofthe assay depend on the ratio of anti-HBc-specific IgM to total IgM (14) . Dilution up to many 1,000-fold in buffer did not alter the results as long as the anti-pt-coated surface remained saturated by IgM. Addition of negative IgM to the sample, however, decreased the binding of IgM anti-HBc. To generate a calibration curve, the reference serum was first diluted 1:2,000 as described above, and this sample was further diluted geometrically by 1:4 in 1% NHP to generate values of 750, 187.5, 46.8, and 11.5 U. The effect of the 1:2,000 dilution was neglected as a constant factor which applied to the reference and test samples. The 1:2,000 working dilution of the reference sample was assumed to contain 3,000 U as well. This is possible because the units define only the proportion of IgM anti-HBc to total IgM and not its absolute amount in a sample.
The absorbancies of the reference series were plotted against a logarithmic scale of the units. IgM anti-HBc units were read for each positive test sample from this calibration curve. To avoid saturation phenomena, samples with more than 750 U were repeated at a dilution of 1:20,000 and the result of this assay was multiplied by 10.
The detection limit was assumed to be 2.1-fold the mean value of the negative samples, which was between 6 and 25 U. Recalcified plasma, containing 100 U of IgM anti-HBc, was deposited in small portions as the national reference sample at the German Institute for Sera and Vaccines (Paul-Ehrlich-Institute, Frankfurt am Main, Federal Republic of Germany). The units of this sample are smaller by a factor of 3.0 than the arbitrary units reported in two previous reports (14, 15 HBsAg and anti-HBc were assayed by solid-phase radioimmunoassay or enzyme immunoassay as described previously (14, 15) .
RESULTS
Optimization of the assay. The assay used for this study was reported in 1979 to work well at a dilution of 1:100 and at a detection limit of approximately 3 U of IgM anti-HBc (15) . During the following years, the binding capacity of the microplates and the anti-pt-chain antibody for total IgM increased considerably. This resulted in an unwanted increase in sensitivity and in prozones with highly positive samples as also recorded by others (28) . Prozones were observed even at dilutions of 1:2,000. To avoid uncomfortably high working dilutions, negative human IgM in the form of 1:100-diluted NHP was used as the diluent for 1:2,000-diluted samples. Under these conditions, the detection limit was 5 to 25 U, and the absorbance of the enzymatic assay product was roughly proportional to the amount of IgM anti-HBc to at least 750 U. Samples with more than 750 U were tested again at 1:20,000 in 1% NHP.
The addition of excess negative IgM also standardizes the amount of total IgM in the sample, which may vary considerably. Under these conditions, the absorbance of the assay was proportional to the endpoint dilution titer. The endpoint titer was, however, not determined for practical reasons in most of the sera. Reading of arbitrary units from a calibration curve was accurate within +20% and much less laborious than endpoint titration. To avoid inconsistent results caused by a variable detection limit, all values below 30 U were considered negative.
The nature of the IgM capture assay requires precautions against nonspecific results caused by rheumatoid factor.
HBcAg from human infected liver always contains some IgG anti-HBc, and this binds to rheumatoid factor as has been noted by others (4) . The conjugate of IgM anti-HBc and peroxidase also contains some rheumatoid-factor-binding components despite purification (4) . An easy way to block out rheumatoid factor is addition of heat-aggregated negative IgG to the diluent of the samples. An amount of 0.5% aggregated IgG has been found sufficient at a 1:100 sample dilution (14) , and this amount was maintained for the 1:2,000 dilution. An additional advantage of this method is that even VOL. 24, 1986 on August 14, 2017 by guest extremely high titers of IgG anti-HBc in the sample are prevented from nonspecific binding to the microplate by a 1,000-fold excess of negative IgG which may otherwise occur (3, 4) .
The assay worked well with HBcAg from both liver and HBV particles which had been isolated from serum. As has been noted by others (8, 18, 29) , the superior source of HBcAg is, however, E. coli which has been transfected with an HBcAg-expressing plasmid. A total of 245 samples were tested in parallel with identical results, using recombinant HBcAg or HBcAg from liver. The titers of IgM anti-HBc were very high in the great majority (Fig. 1A) , and they often exceeded the upper limit (7,500 U) of the quantitation range. Only eight patients (3.7%) had low titers between 30 and 600 U. The sharp discontinuity of the histogram at 600 U (Fig. lA) However, in most of the patients who could be followed up, there was no steady decrease of the titer but instead an irregular titer pattern (Fig. 3) . In several cases the titer was close to the detection limit, and it became transiently positive after negative periods.
A correlation between the titer and the severity of chronic hepatitis could not be deduced from our data. In favor of such a correlation, however, is the fact that asymptomatic HBsAg carriers rarely (4/84) had detectable IgM anti-HBc (Fig. 1C) . Since biopsies were not available, mild liver disease could not be excluded in these four positive persons.
HBsAg-negative, anti-HBc-positive samples. By evaluation of all HBV marker-positive samples, 570 persons were identified who had anti-HBc (total antibody) as a marker of previous or ongoing HBV infection. The absence of HBsAg suggested that the majority of these persons had no active infection. Persons known to have had clinical hepatitis B or transient HBsAg were not included in this group. The great majority of these persons were clinically healthy but belonged to high-risk groups. A significant proportion (17.4%) also had IgM anti-HBc, but titers were mostly below 150 U (Fig. 1D) . The 32 cases (5.8%) with higher titers formed two peaks in the histogram for the titers. In 24 cases the clinical state was known to us. The eight persons with titers higher than 1,200 U (Fig. 1D) One error would be the assumption of non-A, non-B hepatitis in HBsAg-negative cases of acute hepatitis. Such a false conclusion would raise unjustified concerns, because non-A, non-B hepatitis has a much worse prognosis than does HBsAg-negative hepatitis B. However, this form of hepatitis B was less frequent (2.6%) in our study than has been reported by others (22) . This may be due to earlier sample taking, improved detection of HBsAg, exclusion of subclinical cases from the group with acute hepatitis B, or all of these factors. Frequent absence of HBsAg has been reported in fulminant hepatitis B (17, 31) , but such cases were not reported to us.
A second error would be to overlook non-B hepatitis in a chronic HBsAg carrier. In our study with cases from northern Germany, this situation was present in 10% of the HBsAg-positive cases. This is comparable to data from other countries (25, 26) . Here the clinical prognosis is wôrse than in uncomplicated hepatitis B, and close clinical supervision, including liver histology, may be indicated. Hepatitis delta virus was found only once in this group, which is much less than was found in Italy (9, 21) . The relatively high rate of non-A, non-B hepatitis in our group is not surprising, if one takes the similar route of infection into account.
Chronic HBV infection. Evaluation of several hundred HBsAg-positive patients in our study confirmed previous assumptions that a clear cutoff level between acute and chronic HBV infections exists (6, 9, 15, 26, 29, 33) . Owing to the much larger group ofchronic patients, we now adjust this value to a higher level (600 U) than in our previous study (15) . We suggest, however, as do others (12) , that results below this cutoff value not be ignored but that accurate quantitation be carried out. Moderate IgM anti-HBc titers (between 30 and 600 U) are a strong sign of liver disease in a chronic HBsAg carrier as shown by this and other studies (3, (30) (31) (32) 34) . Only if the assay is used in its original, overly sensitive form are healthy HBsAg carriers often positive (1, 10, 11, 15, 20, 28, 31 Standardization of the assay. The scheme of Table 1 is only applicable for IgM capture assays. This type of assay determines the proportion of specific IgM anti-HBc to total IgM. Ideally, it is independent of anti-HBc in other immunoglobulin classes. In its current form it is free of nonspecific side reactions, and it is of high but not excessive sensitivity. All other assays determine the ratio of IgM anti-HBc to total anti-HBc (2, 5, 7, 30) . They may be of advantage during the early acute phase but would be of low sensitivity during late stages or chronic infections. All producers of test kits for IgM anti-HBc and most scientific studies have adopted the IgM capture principle. Use of recombinant HBcAg (8, 18, 29) will further improve the assay.
A generally recognized quantitative reference sample for IgM anti-HBc applicable to all techniques would be highly desirable. Ways to standardize the assay were described previously (14, 33) and applied successfully in this study. A reference sample was deposited at a German control institution, and its validity was confirmed in a cooperative trial involving 29 diagnostic laboratories (R. Thomssen, unpublished data). An international trial and stability studies would be required to establish an international standard.
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